Jazz Pharmaceuticals

Jazz Pharmaceuticals won U.S. regulatory approval for a new leukemia drug aimed at patients who have developed hypersensitivity to E. coli-derived asparaginase, an enzyme that is a component of the chemotherapy regimen used to treat acute lymphoblastic leukemia (ALL).

rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.

Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs during 2020 with a goal of reframing the understanding of the body’s organismal and cellular performance.

The U.S. FDA approved Aries Pharmaceuticals Inc.’s Aemcolo (rifamycin) for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.

Researchers revealed the first U.S. case of a pathogen carrying a mutated strain of E. coli resistant to an antibiotic used as a final defense versus superbugs. As a result, there has been heightened concern that a post-antibiotic era will arrive earlier than predicted.